Literature DB >> 15459510

Impact of age-related cerebral white matter changes on the transition to disability -- the LADIS study: rationale, design and methodology.

Leonardo Pantoni1, Anna Maria Basile, Giovanni Pracucci, Kjell Asplund, Julien Bogousslavsky, Hugues Chabriat, Timo Erkinjuntti, Franz Fazekas, José M Ferro, Michael Hennerici, John O'brien, Philip Scheltens, Marieke C Visser, Lars-Olof Wahlund, Gunhild Waldemar, Anders Wallin, Domenico Inzitari.   

Abstract

Age-related white matter changes (ARWMC) on brain MRI have been associated with cognitive, motor, mood and urinary disturbances. These factors are known to contribute to disability in elderly people, but the impact of ARWMC and of their progression on the transition to disability is not determined. The LADIS (Leukoaraiosis and Disability in the Elderly) study aims at assessing the role of ARWMC as an independent predictor of the transition to disability in initially nondisabled elderly (65-84 years). Subjects who are not impaired or impaired on only 1 item of the Instrumental Activity of Daily Living (IADL) scale, presenting with different grades of ARWMC severity, were enrolled. Eleven European centers are involved. All the patients were assessed at baseline using an extensive set of clinical and functional tests including global functioning, cognitive, motor, psychiatric and quality of life measures. MRI studies were performed at baseline and will be repeated at the end of the follow-up period to evaluate changes of ARWMC and other lesions. ARWMC were categorized into mild, moderate or severe using the scale of Fazekas et al. For each ARWMC severity class, the primary study outcome is the transition to disability defined as an impairment on 2 or more IADL scale items. Secondary outcomes are the occurrence of dementia, depression, vascular events or death. Six-hundred and thirty-nine subjects (mean age 74.13 +/- 5.0 years, M/F: 288/351) were enrolled in a hospital-based setting and are being followed up for up to 3 years. The large and comprehensive set of measures in LADIS enables a comprehensive description of their functional and clinical features to be examined in relation to different morphological patterns and severity of ARWMC. The longitudinal design will give insight into the possible role of ARWMC and their progression as an independent contributor to disability in the elderly, eventually helping to develop preventive strategies to reduce the burden of disability in late life. The study results may also help to standardize, on an international basis, tools and criteria to identify early stages of disability.

Entities:  

Mesh:

Year:  2005        PMID: 15459510     DOI: 10.1159/000081050

Source DB:  PubMed          Journal:  Neuroepidemiology        ISSN: 0251-5350            Impact factor:   3.282


  100 in total

1.  Functional evaluation distinguishes MCI patients from healthy elderly people--the ADCS/MCI/ADL scale.

Authors:  H Pedrosa; A De Sa; M Guerreiro; J Maroco; M R Simoes; D Galasko; A de Mendonca
Journal:  J Nutr Health Aging       Date:  2010-10       Impact factor: 4.075

Review 2.  The challenge of mixed cerebrovascular disease.

Authors:  Mark Fisher
Journal:  Ann N Y Acad Sci       Date:  2010-10       Impact factor: 5.691

3.  Cognitive profile in CADASIL patients.

Authors:  L Caeiro; J M Ferro
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-02       Impact factor: 10.154

4.  Cerebral blood flow by using pulsed arterial spin-labeling in elderly subjects with white matter hyperintensities.

Authors:  A J Bastos-Leite; J P A Kuijer; S A R B Rombouts; E Sanz-Arigita; E C van Straaten; A A Gouw; W M van der Flier; P Scheltens; F Barkhof
Journal:  AJNR Am J Neuroradiol       Date:  2008-05-01       Impact factor: 3.825

5.  Age-related changes in short-latency motor cortex inhibition.

Authors:  Ashleigh E Smith; Michael C Ridding; Ryan D Higgins; Gary A Wittert; Julia B Pitcher
Journal:  Exp Brain Res       Date:  2009-07-19       Impact factor: 1.972

6.  Depressive symptoms as a predictor of quality of life in cerebral small vessel disease, acting independently of disability; a study in both sporadic small vessel disease and CADASIL.

Authors:  Rebecca L Brookes; Thomas A Willis; Bhavini Patel; Robin G Morris; Hugh S Markus
Journal:  Int J Stroke       Date:  2012-02-26       Impact factor: 5.266

7.  The burden of microstructural damage modulates cortical activation in elderly subjects with MCI and leuko-araiosis. A DTI and fMRI study.

Authors:  Mario Mascalchi; Andrea Ginestroni; Nicola Toschi; Anna Poggesi; Paolo Cecchi; Emilia Salvadori; Carlo Tessa; Mirco Cosottini; Nicola De Stefano; Giovanni Pracucci; Leonardo Pantoni; Domenico Inzitari; Stefano Diciotti
Journal:  Hum Brain Mapp       Date:  2012-12-08       Impact factor: 5.038

8.  Differential impact of cerebral white matter changes, diabetes, hypertension and stroke on cognitive performance among non-disabled elderly. The LADIS study.

Authors:  Ana Verdelho; Sofia Madureira; José M Ferro; Anna-Maria Basile; Hugues Chabriat; Timo Erkinjuntti; Franz Fazekas; Michael Hennerici; John O'Brien; Leonardo Pantoni; Emilia Salvadori; Philip Scheltens; Marieke C Visser; Lars-Olof Wahlund; Gunhild Waldemar; Anders Wallin; Domenico Inzitari
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-04-30       Impact factor: 10.154

9.  White matter hyperintensities and medication adherence.

Authors:  Kathleen C Insel; Sheryl L Reminger; Chao-Pin Hsiao
Journal:  Biol Res Nurs       Date:  2008-10       Impact factor: 2.522

10.  Changes in white matter as determinant of global functional decline in older independent outpatients: three year follow-up of LADIS (leukoaraiosis and disability) study cohort.

Authors:  Domenico Inzitari; Giovanni Pracucci; Anna Poggesi; Giovanna Carlucci; Frederik Barkhof; Hugues Chabriat; Timo Erkinjuntti; Franz Fazekas; José M Ferro; Michael Hennerici; Peter Langhorne; John O'Brien; Philip Scheltens; Marieke C Visser; Lars-Olof Wahlund; Gunhild Waldemar; Anders Wallin; Leonardo Pantoni
Journal:  BMJ       Date:  2009-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.